|
Report Date : |
03.05.2013 |
|
|
|
|
Tel. No.: |
880 2 9840523 32 |
IDENTIFICATION DETAILS
|
Name : |
INTERNATIONAL
CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH |
|
|
|
|
Registered Office : |
68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka-1212 |
|
|
|
|
Country : |
Bangladesh |
|
|
|
|
Date of Incorporation : |
1978 |
|
|
|
|
Legal Form : |
Organization |
|
|
|
|
Line of Business : |
Research Centre Oral Rehydration Solution |
|
|
|
|
No. of Employees : |
500 |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Bangladesh |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Bangladesh - ECONOMIC OVERVIEW
In real terms Bangladesh's economy has grown 5.8%
per year since 1996 despite political instability, poor infrastructure,
corruption, insufficient power supplies, and slow implementation of economic
reforms. Bangladesh remains a poor, overpopulated, and inefficiently-governed
nation. Although more than half of GDP is generated through the service sector,
45% of Bangladeshis are employed in the agriculture sector with rice as the
single-most-important product. Bangladesh's growth was resilient during the
2008-09 global financial crisis and recession. Garment exports, totaling $12.3
billion in FY09 and remittances from overseas Bangladeshis, totaling $11
billion in FY10, accounted for almost 12% of GDP
|
Source : CIA |
|
Name |
International Centre for Diarrhoeal Disease Research, Bangladesh |
|
Address |
68 Shaheed
Tajuddin Ahmed Sarani, Mohakhali,
Dhaka-1212 |
|
Country |
Bangladesh |
|
Telephone No |
880-2-8823031 |
|
Fax No |
880-2-8823116 |
|
E-Mail |
|
|
Website |
|
|
Established |
1978 |
|
Legal Status |
Organization |
|
Business Type |
Research Centre |
|
Status |
Satisfactory |
|
Payment Behavior |
No complaints have been heard regarding payments from local
suppliers or banks. |
|
Head Office |
68 Shaheed
Tajuddin Ahmed Sarani, Mohakhali,
Dhaka-1212 |
|
Telephone No |
880-2-8823031 |
|
Fax No |
880-2-8823116 |
|
E-Mail |
|
|
Website |
www.icddrb.org |
|
Branch |
NIL |
|
Hospitals |
4 Dhaka 4 Matlab |
|
Factory Telephone No |
N/A |
|
Factory Fax No |
N/A |
|
Warehouse |
128 Mohakhali, Dhaka-1000 |
|
Name |
Dr. Abbas Bhuiya |
|
Designation |
Deputy
Executive Director |
|
Nationality |
Bangladeshi |
|
Line of Business |
Research Centre |
|
Items Dealing In |
Oral Rehydration Solution |
|
Terms of Purchase |
Local: Cash or Credit Import: Against L/C |
|
Terms of Sale |
Local: Cash or Credit |
|
Name |
Sonali Bank Limited |
|
Branch |
Mohakhali Branch |
|
Address |
Mohakhali C/A, Dhaka |
|
SWIFT |
N/A |
Note: The financial information of the subject could not be obtained.
|
Authorized
Capital |
N/A |
|
Paid Up Capital |
N/A |
|
Each Share Value |
N/A |
|
Currency |
Unit |
Bangladeshi Taka (BDT) |
|
Great Britain Pound |
1 |
120.8148 |
|
U.S Dollar |
1 |
77.9400 |
|
European Euro |
1 |
102.1014 |
|
Dishonored
Checks |
No Found |
|
Debt |
No Records Found |
|
Litigation |
No Records Found |
|
Performance
Defaults |
No Records Found |
|
Adverse Press
Coverage |
No Records Found |
|
Money Laundering |
No Records Found |
|
Employees |
500 |
|
Office Area (Sq.
Ft) |
UNKNOWN |
|
Hospital Area
(Sq. Ft) |
UNKNOWN |
|
Warehouse Area
(Sq. Ft) |
UNKNOWN |
|
Range of
Services |
4 Translating our
research expertise 4 Clinical and diagnostic services 4 Humanitarian
services in response to emergencies, both within and outside
Bangladesh 4 Family Planning
|
|
Donors |
4 Australian
International Development Agency (AusAID) 4 Government of
Bangladesh (GoB) 4 Canadian
International Development Agency (CIDA) 4 Embassy of the
Kingdom of the Netherlands (EKN) 4 Swedish
International Development Cooperative Agency
(SIDA) 4 Department for
International Development, UK (DFID). 4 ACME
laboratories Ltd. 4 ActionAid
International 4 Akthelia Pharmaceuticals,
Iceland 4 Alliance for
Health Policy and Systems Research, WHO 4 AusAID, Australia 4 AusAID,
Bangladesh 4 Bill &
Melinda Gates Foundation, USA 4 BRAC,
Bangladesh 4 BRAC Bank
Limited, Bangladesh 4 Canadian
International Development Agency (CIDA), Canada 4 CARE Bangladesh 4 Centers for
Disease Control and Prevention, USA 4 Cincinnati
Children's Hospital Medical Center, USA 4 The City
University of New York, USA 4 Columbia
University, USA 4 CTK Biotech,
Inc. USA 4 Department for
International Development (DFID), UK 4 Professor
Gudmundur Hrafn Gudmundsson, University of Iceland 4 Dutch Bangla
Bank Foundation, Bangladesh 4 Embassy of the
Kingdom of the Netherlands (EKN), Bangladesh 4 Emory
University, USA 4 Food and
Agriculture Organization of the United Nations (FAO) 4 Global Fund for
AIDS, TB and Malaria (GFATM) 4 Government of
the People's Republic of Bangladesh (GoB) 4 GTZ, Germany 4 Gynuity Health
Projects 4 Harvard Medical
School, USA 4 HarvestPlus,
USA 4 InBios
International, Inc., USA 4 IHSD -
Institute for Health Sector Development Limited, UK 4 International
Atomic Energy Agency (IAEA), Austria 4 International
Vaccine Institute (IVI), South Korea 4 Ipas, USA 4 IZUMI
Supporting Community (ISC), Japan 4 Japan Food
Hygiene Association (JFHA) 4 Johns Hopkins
Bloomberg School of Public Health, USA 4 Johns Hopkins
University (JHU), USA 4 KNCV
Tuberculosis Foundation, Netherlands 4 London School
of Hygiene &Tropical Medicine 4 Lund University
, Sweden 4 Malaria
Research Initiative Bandarban (MARIB) 4 Malta Grants
for Leprosy Research, France 4 Massachusetts
General Hospital (MGH), USA 4 MP Biomedicals
Asia Pacific Pte. Ltd. 4 Napo India
Private Limited, India 4 National Heart
Lung and Blood Institute (NHLBI), NIH 4 National
Institute of Infectious Diseases (NIID), Japan 4 Nestec Ltd.,
Switzerland 4 Novartis
Consumer Health S.A., Switzerland 4 PATH, USA 4 Pathfinder
International, USA 4 Professor
Ronald G. Barr, UBC, Canada 4 Research
Institute for Humanity and Nature (RIHN) 4 Save the Children,
USA 4 Seattle
Biomedical Research Institute, USA 4 SmithBucklin
Corporation 4 Swedish
International Development Cooperation Agency (Sida), Sweden 4 TechLab, Inc., Virginia, USA 4 INDEPTH Network 4 The Oxford
Health Alliance Vision 2020 (OxHA) 4 The Rockefeller
Foundation 4 World Food
Programmed (WFP) 4 Wildlife Trust,
USA 4 Thrasher
Research Fund, USA 4 UNICEF,
Bangladesh 4 United Nations
Development Programme (UNDP), Bangladesh 4 United States
Department of Agriculture (USDA) 4 University of California,
Berkeley, USA 4 University of
California, Davis, USA 4 University of
Chicago, USA 4 University of
Maryland, USA 4 University of
North Carolina at Chapel Hill, USA 4 Utrecht
University, Netherlands 4 University of
Virginia, USA 4 UBS Optimus
Foundation, Switzerland 4 Vanderbilt
University, USA 4 Venture
Strategies Innovations, USA 4 Veolia
EAU-Compagnie Generale des Eaux S.C.A., France 4 World Health
Organization (WHO), Geneva 4 World Health
Organization (WHO), Malaysia 4 Zephyr
Biomedicals, India |
|
Certifications |
NIL |
|
Group Name |
NIL |
|
Subsidiaries /
Affiliates |
NIL |
|
Member |
4 World Health
Organization (WHO) |
|
Business Scale |
Fairly Large |
|
Business Trend |
Growing |
|
Management
Capability |
Good |
|
Reputation |
Good |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.73 |
|
|
1 |
Rs.83.54 |
|
Euro |
1 |
Rs.70.71 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.